Welcome to the CliniSys Group Blog

With over 30 years’ experience in developing and installing healthcare IT solutions, our skilled and dedicated teams have much to share. From useful advice from a recent multi-site deployment to generic handy hints to support and maintain IT solutions in a critical 24/7 healthcare environment, our blog posts are designed to educate, inform and interest all.

Featured Blog

How Covid will shape the coming year and help to change pathology forever

Richard Craven, chief executive of CliniSys, considers how the tumultuous events of 2020 will impact on 2021, and how they will affect the company, the NHS, and the world of pathology for years to come. Twenty-twenty was an exceptional year. I doubt any of us will forget the arrival of the coronavirus or the impact […]

Read full article

How Covid will shape the coming year and help to change pathology forever

Richard Craven, chief executive of CliniSys, considers how the tumultuous events of 2020 will impact on 2021, and how they will affect the company, the NHS, and the world of pathology for years to come.

Twenty-twenty was an exceptional year. I doubt any of us will forget the arrival of the coronavirus or the impact it had on our NHS, our working lives and our family lives. The impact of Covid-19, and our response to it, will shape next year and will be felt well into the future.

So, here are my top ten thoughts on how Covid-19 has changed CliniSys, the NHS, pathology and the clinicians and patients it serves, and how we will all continue to feel its effects in the future.

One: Remote working works: One of the things that has worked exceptionally well for us as a company is remote working. I know people value the flexibility it offers and the way in which it has enabled them to achieve a much better work-life balance. It has also made us more outcome focused: within limits, people can do what they need to do when they need to do it. That will continue: not just in 2021, but probably for the rest of our working lives.

Two: The office is not dead, but it is changing: As the UK went into its first lockdown in March, I thought we might close all our physical offices or downsize them hugely. Now, I don’t believe that will happen, but I do think that the office will change. Our office in Chertsey is showing the way and we are looking for a more contemporary office space for our Glasgow teams. It will be much more café-style: a place where people can meet together as a team, redouble their energy and enhance their creativity by being together before they return to remote/flexible working until the next office-based get together.

Three: The NHS has embraced digital technology: We have seen the changes at CliniSys reflected in our customers. The NHS has gone through a very rapid uptick in terms of the adoption of digital technology, but we are only just at the start of that. There has been a significant adoption of remote working and virtual consultation technology, but the next step will be a move towards digital everything: health and wellbeing advice, remote follow-up and monitoring, patients becoming more active participants in their care via apps and other digital technologies.

Four: In pathology, surveillance is here to stay: Twenty-twenty is going to lead to some permanent changes to pathology services. We have seen a huge investment in testing to track the spread and impact of Covid-19 and I think surveillance will get more investment and development. Some of that will be about making sure we are ready for the next public health incident. But there will also be further investment in diagnostic services and technology to increase capacity as demand for diagnostic testing increases and as new diagnostic innovations become mainstream.

Five: Data is key: Twenty-twenty has also underlined the importance of data. In the absence of good data, decision makers and clinicians have struggled to make good decisions about Covid-19. CliniSys processes data for something like 60% of pathology in the UK, so we need to help our clinicians to use that data to manage their business, predict and manage demand, speed up and aid diagnosis and fully digitise processes.

Six: Data needs to join-up: We also need to start joining up pathology data with other kinds of medical data, from the observations that doctors and nurses make, to the genomic information that will be handled by our new genomics LIMS, GLIMS Genomics. We continue to develop ways in which our software can link to the collaborative tools that so many people have started using this year, so we can get data into multi-disciplinary team meetings and other settings where clinicians are discussing results and taking treatment decisions.

Seven: We’re on the cusp of computational pathology: We continue to explore how AI and machine learning can further enhance our solutions so that, as diagnostic data becomes fully digitised, smart use can be made of data to help our customers run their labs and clinicians at the workbench make better, more informed decisions. As this happens, pathology will move from the back room to its rightful place at the heart of the clinical process.

Eight: Pathology work will be reimagined: “If people can work from anywhere, they will work from anywhere. We have already seen this in radiology; radiologists have set up at home or in shared offices in ways that suit them, with large, high resolution screens, and instead of them going to work, work has come to them. As digital pathology becomes the norm, I think we will see the same happen in pathology, which will enable pathologists to work for multiple hospitals and organisations. Our challenge will be to build tools to support them.

Nine: There’s no equilibrium in business: One of the first things that I learned in my career is that ‘there is no equilibrium in business’ and Covid has proved it. At CliniSys, we are thinking constantly about how to remain durable and relevant in a world that can change – snap of fingers – just like that. We need to help our customers respond to the new environment, whether that’s by doing simple things, like building some smarts into our Integrated Clinical Environment (ICE), to direct tests away from labs that are becoming overwhelmed, or complex ones, like developing technology that will meet the need of new services, like regional diagnostic hubs.

Ten: Amazonification is here: Finally, we should not forget about the patient. Even before the pandemic, people were starting to think about the Amazonification of healthcare services, and that trend has just been given a significant boost, as work, shopping and socialising has moved online. Patients are going to want to be able to order their own tests and get direct access to their results, book and cancel appointments. The immediacy of digitisation is something that healthcare is going to have to deal with and I expect it to have some interesting impacts in 2021 and beyond.

Read full article

A vision for diagnostic services across Scotland

The Integrated Clinical Environment, or ICE, is used in seven out of the 14 health boards in Scotland for order communications and results reporting. Imagine if it was used across Scotland, as a single point of information about tests of all kinds… At a recent webinar, CliniSys outlined the art of the possible.

 “Today,” said Richard Craven, “I want you to imagine the art of the possible.” Imagine, the chief executive of CliniSys told a recent webinar, that just one year from now any clinician, anywhere in Scotland, could order any test and see the results alongside the results of any other test conducted for their patient.

Then imagine that any other clinician contributing to the care of that patient could see the same information within their current system. A pipedream? Not a bit of it. Craven told his audience that the technology required not only exists; but is in use in half of the health boards in Scotland.

It is the Integrated Clinical Environment, or ICE, an order communications and results reporting solution, that is being developed to support shared service models and can be accessed through a portal. Or, as Craven put it: “How do we bring this to reality? CliniSys’ answer is ICE. It is in use in seven out of the 14 health boards in Scotland; so you are half-way there.

“And we are working to build regional ICE hubs in England, starting in London and the South West. So, we are confident we can do this and extend the concept of ‘right test, right time, right place’ to… ‘from anywhere’.”

The Integrated Clinical Environment: built for integration

CliniSys ICE is a user-friendly electronic testing and results reporting service that has been designed to integrate with electronic patient record,  laboratory information systems and a range of other diagnostic systems that support international messaging standards, such as those produced by HL7.

This means it can cope with a mixed environment of EPR and LIMS systems, and enable health boards to get the most out of their investment by leaving them in place while extending their use. Other features support health boards that want to move quickly towards shared service models.

For example, OpenNET allows one instance of ICE to talk to another instance of ICE, while the ICE application programming interface, or API, enables it to integrate with third-party systems. Users can order and view results through the ICE portal,  to safely identify patients and draw together their results.

ICE product manager Gerald Blair explained that CliniSys has worked hard to make sure that ICE can better work with a number of local and national identifiers. Naturally, these include Scotland’s community health index, or CHI, number, which is mandated on all clinical communications.

Another feature of ICE enables a lab using one instance of ICE to publish a catalogue to another instance. The organisation running the second ICE system can choose whether to make some or all of the catalogue visible to its users. But if it does, clinicians can “mix and match” the tests that they order; and see the results in that one, consolidated view.

“Published services is a new view that allows a laboratory to publish some or all of its services to another ICE system, which means that you can share services across a region or individual hospital laboratories in a distributed system,” Blair summarised. “The reporting aspect means that users of one ICE system can see results from other services, no matter how they are configured.”

ICE in action

So, how does it work in practice? Blair gave two examples. In the first, two health boards want to consolidate some of their laboratory services, to make the most of expensive equipment and scarce clinical expertise.

Until recently, to do this, board A would have had to configure its LIMS and order comms systems to align with those of board B, and then keep everything in sync. But by using ICE, with its published services functionality, board B can publish a catalogue to board A, and board A’s clinicians can use it.

In the second example, one or more health boards want to set up a regional laboratory system on a hub and spoke model, in which one lab conducts specialist tests and others handle ‘hot’ work. To do this, all the labs implement a single instance of ICE and use it as both a catalogue and results repository.

“This allows for the customisation of not just one service but many services across a region, driving improved service optimisation for the labs, and delivering a higher quality of service,” Blair explained.

“Meanwhile, users get a longitudinal view of a patient’s diagnostic history, which reduces unnecessary testing, because all the results from the central repository can be presented at the time of the test. It also reduces time for the clinician, because they can easily locate and view this information, if it is there.”

The ICE diagnostic hub

 If every health board in Scotland used ICE and used it to move from a regional to a national shared service model by publishing their labs’ catalogues to each other, the country would be a long way down the road to the vision set out by Craven.

But there is a final part of the picture, which is to bring in other tests as well. Blair explained that this can be done by integrating ICE with the systems used by other diagnostic areas, such as radiology and cardiology, using the ICE API. Users can then order tests and view results in the ICE diagnostic hub.

Blair argued that the case for doing this is that it’s not just pathology that is starting to operate on a regional or networked model. Many other services are moving in the same direction, which means that patient pathways increasingly span multiple specialities and locations.

If their information isn’t available to the clinicians in all those locations, there can be gaps in the record. The ICE diagnostic hub concept closes those gaps. “There are many benefits,” Blair said. “It takes less time for clinicians to find this information, it further reduces the need for repeat testing, it should mean a better diagnosis – first time. It also supports clinical audit and data analytics.”

Right test, right place right time… from anywhere

The webinar was shown examples of how the ICE diagnostic hub looks to users, who can rapidly configure its widgets to create patient, task and results lists to support their work, and then drill down into individual results or graph them over time.

Organisations that do not use the ICE diagnostic hub can use the ICE API to give their clinicians access through their electronic patient record. The event concluded with a rapid tour of some extensions and improvements that were made to ICE during the Covid-19 pandemic.

These include a stripped-down version of the ICE portal to enable care homes to order COVID tests in bulk, and a platform to enable staff to receive negative results by text; both of which are available for new and creative uses once the NHS in Scotland starts to recover.

The NHS in Scotland, as in other areas of the UK, has seen huge changes in its use of technology during the pandemic; and is now looking for ways to build on that momentum. In his introduction, Craven argued that new thinking on diagnostic technology needs to play its part. “Right test, right place, right time, from anywhere,” he said. “CliniSys can help to make this possible.”

Webinar recording
If you would like a link to the recording of the event or would like to find our more then please email matthew.fouracre@clinisys.co.uk
Read full article

West Yorkshire and Harrogate Pathology Network secures major contract for CliniSys LIMS

Design and implementation work is underway on the deployment of WinPath Enterprise to the ten labs in the West Yorkshire and Harrogate Pathology Network

The hosted solution will support standardisation across the network that covers a patient population of 2.6 million and handles more than 50 million tests a year, ahead of the opening of a new laboratory in Leeds in 2023

A major step in the transformation of pathology services in West Yorkshire and Harrogate has been taken, with the award of the largest laboratory information management system (LIMS) contract won by CliniSys.

The contract will support the West Yorkshire and Harrogate Pathology Network to safely and effectively handle more than 50 million tests a year.

The deal will see WinPath Enterprise deployed to the four pathology providers in the network, which are Leeds Teaching Hospitals, Mid Yorkshire Hospitals, and Calderdale and Huddersfield NHS foundation trusts, with Integrated Pathology Solutions, an LLP that serves Airedale, Bradford Teaching Hospitals and Harrogate and District NHS foundation trusts.

Deployment will start in Leeds, ahead of the opening of a state-of-the-art pathology facility at St James’s University Hospital, which was given the green light by planners in August 2020 and is due to open in spring 2023.

Lucy Cole, the programme lead for West Yorkshire and Harrogate Pathology Network, said: “A shared LIMS across the network will support us to standardise ways of working between laboratories, and WinPath Enterprise will provide a resilient and sustainable solution for the future.

“A significant amount of background work, including planning, designing and testing the system will take place to prepare for the roll-out. Pathology colleagues from all trusts will be involved in designing the new system and processes.”

Design and implementation work will be carried out remotely because of the Covid-19 pandemic.

The timeline for the roll-out has also been constructed to make sure that staff working at all six trusts can be engaged with the project, despite the additional pressure caused by the present Covid-19 pandemic.

Donald Saum, senior business development director at CliniSys, said: “This is a fantastic win for CliniSys and we are delighted to have been selected as an enabling partner, supporting a significant change for West Yorkshire and Harrogate Pathology Network.

“We are very much looking forward to working with everybody involved in the deployment project, to make sure they get the full benefit of their investment in our technology.”

WinPath Enterprise has been built to meet the needs of modern pathology networks. WinPath enables the management, tracking, interpretation and clinical diagnosis of all types of specimens across all disciplines. WinPath also helps the pathology service to standardise workflows, adhere to clinical regulations to improve efficiency, deliver a quality service for clinicians and patients and provide data analytics to enhance clinical decision making.

The network has opted to take a hosted version of WinPath Enterprise, which means that CliniSys will be responsible for the running and upkeep of the system.

Although this is the biggest single contract that CliniSys has secured for WinPath Enterprise, the company has a track record of delivering for the NHS with greater than 50% of NHS Trusts using its LIMS.

Read full article

‘Joining the dots’ – Newly appointed Group Marketing Director at CliniSys, Paul Jackson, provides an introduction and some initial observations

When you look at some of the stats from the CliniSys Group, our success is impressive.

  • CliniSys processes data for circa 60% of pathology in the UK and has leading market shares across Europe for Laboratory Information Management Systems.
  • The UK’s leading order communications platform – Integrated Clinical Environment (ICE), with over 40 million tests ordered by GPs each year and 35% of the acute sector market share. The software also underpins national NHS services such as England’s HPV screening

Such an impressive background and pedigree lays a great foundation for a senior marketer to build further at CliniSys. For this unassuming organisation, that quietly and efficiently developed solutions that have become the backbone of many healthcare systems across Europe, now is the time for CliniSys to step out of the shadows.

A graphic designer by trade, I have spent over 20 years working within healthcare IT supplier organisations developing and building their marketing infrastructure to maximise strategic and commercial goals. In its simplest form at CliniSys, it is about ‘joining the dots’ and bringing the organisation together as one powerful brand and voice. Marketing planning is already underway and starting in the first quarter of 2021 there will be a series of initiatives to support the CliniSys Group’s marketing and corporate goals.

‘Joining the dots’ already seems to be my common phrase for 2021. A positive consequence of 2020 was the significant improvement in the way we collaborate, and it will continue to develop in 2021. Also, 2020 drove our ability to look at things in a different way to maximise (and enhance) the benefit, by extending technology that already exists, so it can be applied further and wider across health and social care.  CliniSys has been adept at extending its existing technology and deployments to meet some of the most challenging aspects of the pandemic, specifically in support novel and mass testing and the rapid reporting of COVID-19 results back to key workers and citizens.

Whilst I am new in post, attributes that became quickly clear are the strength, determination, and passion right across the organisation to get the job done, even with the challenges that 2020 brought. Incorporate marketing into this and you can amplify those attributes and the outcomes further and wider.

The continued success of the CliniSys Group is also another mechanism that marketing will continue to use to strengthen the message. And it is not just about the ongoing contract wins, which are fantastic, but it is also about successful deployments or new product releases, and the tangible benefits and improvements they bring to our customers. Whether it be an individual deployment or network approach, our customer stories will continue to be told and shared. The recent launch of GLIMS Genomics in the UK has also been positively received and we are already speaking to several Genomic Laboratory Hubs and Local Genomic Laboratories.

2020 has reset many things and marketing is very much included, especially around physical face to face events, which are always an important part of the calendar. Marketers have had to change approaches and look at things in a completely different way, enabling the use of different media  and creative approaches. This will continue in 2021 and become adapted as another element of the marketer’s toolkit.

Read full article

Why genomics labs should look for bespoke LIMS, and not fall back on the EPR

CliniSys has brought GLIMS Genomics to the UK. In a launch webinar, experts explained how the new laboratory information system built for genomics labs can put them in charge of their IT, drive standardisation, and deliver reports that clinicians can use as they move into the exciting world of precision medicine. And Dr Fabienne Dufernez explained how these benefits are already being delivered in Poitiers University Hospital.

This summer, Steve Abbs pointed out that we have reached an interesting point in the development of genomic medicine in the UK. The experienced laboratory director, who is acting as a genomics consultant to CliniSys, blogged that genomic testing is no longer the preserve of few, small, research groups.

Instead, it is on the verge of becoming an established diagnostic tool for some cohorts of patients, and on the way towards becoming a routine part of precision medicine. In recognition of that, the NHS in England established a national Genomic Medicine Service, delivered by seven genomic laboratory hubs that will, between them, deliver the National Genomic Test Directory.

However, Abbs argued that if the GLHs are going to do what is hoped, they are going to need good IT; both to deliver an effective, standardised service, and to make sure results are accurately interpreted and linked back to patient histories.

Now, CliniSys has formally launched GLIMS Genomics in the UK; a laboratory information system built for genomics labs with these requirements in mind. It is already being successfully deployed at Poitiers University Hospital in south west France, and will soon be deployed in seven further genomics laboratories across Europe.

Why not just use the EPR?

Genomics labs do have other options, Abbs acknowledged on a launch webinar.  For example, they could choose to use the electronic patient record of the trust hosting them. However, he argued that a LIMS and an EPR are fundamentally different creatures – “an EPR is based around patient encounters, while a LIMS is built around specimens” – and there are other factors to consider.

For instance, if the EPR ‘goes down’ then the laboratory will ‘go down’ with it and might not find itself at the front of the queue when it comes to getting up and running again. Or, if the lab needs a bug fix or new feature, it could find itself competing with other departments for the limited resources of the trust’s IT team.

With a “bespoke” LIMS, these issues don’t arise. Or, as Abbs put it: “You, as a lab, are in complete control of it, along with your supplier. With an EPR, your hospital is in control. Whereas, with a purpose built LIMS, you are in control.”

Built for the needs of genomics labs

Plus, there is that very important distinction that an EPR and a LIMS are built to do different things. Emma Huntridge, genomics business development director at CliniSys, told the webinar that GLIMS Genomics builds on the company’s extensive experience of working with laboratories to handle specimens in the most effective way possible.

“The CliniSys Group is based in the UK and Europe and has more than 30 years’ experience of delivering IT solutions,” she said. “We are now the largest European LIMS provider, while in the UK we predominantly work with trusts to implement pathology network solutions.

“Our new LIMS for genomics laboratories combines the strength of a mature LIMS for routine diagnostic laboratory areas with functionality to meet the special requirements of genomics.”

For example, Huntridge showed the webinar one of the graphical features of GLIMS Genomics, which enables labs to build simple or highly complex workflows, known as “approach plans”. These lay down the standard procedures for all workflows in the laboratory, including booking in samples, determining how their genetic material should be extracted, running tests, concluding this process, and reporting results.

The approach plans are visible at the bottom of the screens that laboratory technicians use at each step, so they can readily see what has been done and what should happen next. The approach plans and the screens themselves are highly configurable, so labs have flexibility about how much information is recorded throughout a procedure, and privacy controls ‘screen’ sensitive fields from users who do not need to see them.

Solving the IT puzzle at Poitiers University Hospital

Another graphical feature of GLIMS Genomics is the “pedigree tool” which enables the user to construct a family tree for a patient and to map their genetic inheritance onto it. Huntridge demonstrated how she could construct a family tree for pregnant ‘Anne Long’ showing that her parents were carriers of the cystic fibrosis gene and her brother died from a complication of the disease.

She also demonstrated how she could create a report for her clinicians that can include interpretive data from leading global databases and charts or tables from different systems.

Earlier in the webinar, Dr Fabienne Dufernez, senior cytogeneticist and quality manager at Poitiers University Hospital, was able to show a real (but, of course, anonymised) report from her hospital populated with data from GLIMS Genomics, which is just in the final stages of being deployed.

Dr Dufernez explained that all genetic testing is carried out in university hospitals in France because of its complexity. Her own hospital wanted to streamline its workflows and to standardise the approach taken to the different tests that it conducts.

“We needed a way to bring together different parts into one system,” she said, “because previously it looked like a puzzle [as] everybody used different tools to do the same work.” Now, she added, “GLIMS Genomics handles all the work, from reception, to extraction, to analysis, validation and reporting” and the hospital is seeing significant benefits as a result.

Supporting labs now, ready for the precision medicine future

One of those benefits is that the laboratory has access to dashboards that make it simple for managers to see, at a glance, how much work has been completed, and what tests are being run.

Additionally, Huntridge explained: “The system can generate a report on whatever data has been collected. So, if you have data that needs to go to NHS England/Improvement, for example, then it can be sent to them; or it can be analysed internally to drive efficiency and quality improvements.”

Still, that is hardly where the true potential of GLIMS Genomics lies. As Huntridge, who was formerly national genomics informatics lead for NHS England/Improvement pointed out, the system has been designed as “an optimised genomics LIMS that will meet current and future requirements.”

And, as such, it is: “Aligned with the strategy for greater inclusion of genomics in broader healthcare, and particularly the development of personalised patient care and precision medicine.”

Read full article

MIPS choisi par le gouvernement français pour contribuer à la prévention de l’épidémie de Covid-19

Dans le cadre de la gestion de l’épidémie, la détection et le traçage des cas positifs de Covid-19 sont déterminants pour la réussite de la sortie de crise et à la protection de la population française. C’est l’objectif du projet national SI-DEP, mis en place par le ministère des solidarités et de la santé, pour lequel, MIPS en partenariat avec l’AP-HP a été choisie et missionnée. Sa solution de prescription connectée et de consultation de résultats en ligne CyberLab est le cœur du processus informatique de la plateforme SI-DEP.

La plateforme a été réalisée en moins de deux mois. À ce jour il y a au total 374 centres hospitaliers et environ 4 500 laboratoires privés connectés à la plateforme. Cette connexion est bidirectionnelle :  d’un côté la prescription de tests Covid-19 et d’un autre la diffusion des résultats. Dans la première phase, seul le dépistage PCR était remonté dans SI-DEP. Ensuite ont été intégrés les tests sérologiques, puis les tests rapides. Depuis mi-novembre, les pharmaciens, les infirmières et les médecins libéraux alimentent également la plateforme, ainsi le nombre de tests journaliers sera amené à dépasser 500.000.

« Nous sommes fiers d’avoir réalisé la plateforme SI-DEP en seulement six semaines, » souligne Nicolas Blanc, directeur commercial France et Suisse chez MIPS. « Cette réalisation est le fruit d’un travail collectif, et nous tenons à remercier nos partenaires, et notamment les équipes de l’AP-HP qui ont fait un travail remarquable ainsi que la société Enovacom, spécialiste de l’interopérabilité et de la sécurité des données. »

Repérer, tester et isoler

Mettre en œuvre un dépistage virologique de grande ampleur au niveau national, afin de contrôler et limiter une reprise de l’épidémie et piloter finement la dynamique de contamination sur le territoire, dépend de la capacité à repérer, tester et isoler les malades et les cas contacts. Cette mission d’intérêt public et prioritaire est assurée par le projet SI-DEP, qui repose sur un partenariat entre le ministère français des solidarités et de la santé, l’assistance publique – hôpitaux de Paris (AP-HP), Santé publique France, ainsi que les laboratoires de biologie médicale et les éditeurs de système d’information de laboratoire.

Une plateforme temps réel et sécurisée

Visant à informatiser ce processus de dépistage, SI-DEP (Système d’Informations de DEPistage) est une plateforme sécurisée d’enregistrement et de transmission des résultats des laboratoires de tests Covid-19, permettant de s’assurer de la prise en charge des cas positifs. Il s’appuie sur une collecte en temps réel, exhaustive et immédiate des résultats qui permet de briser la chaîne de contamination.

Pour ce projet, contraint dans le contexte par des délais particulièrement serrés, le ministère des solidarités et de la santé a missionné MIPS, dont la solution CyberLab permet aux laboratoires, de manière fluide, fiable, transparente et sécurisée, de gérer les demandes d’examen et la communication de résultats.

Avec sa capacité à s’interfacer avec tous les systèmes d’information de laboratoire (SIL), sa grande facilité de déploiement sous la forme d’une application web, sa capacité à traiter de grands volumes sur plusieurs établissements, CyberLab répondait aux exigences hors normes d’un tel projet et s’est ainsi placée au cœur de l’architecture du SI-DEP. MIPS bénéficiait en outre dans ce domaine d’une expérience en Belgique où la solution CyberLab a déjà été exploitée dans un contexte similaire pour une plateforme nationale de tests.

Moins de deux mois pour être opérationnel

Opérationnel depuis le 13 mai, avec une montée en charge progressive, le projet s’articule autour de quatre fonctions principales :

  • La mise à disposition d’un outil de prescription connectée multi établissements et multi SIL.
  • La centralisation de l’ensemble des résultats de dépistages PCR et sérologiques du territoire national (privés et publics), sous la forme d’une base nationale, les données étant hébergées par l’AP-HP, l’ensemble du traitement opérationnel s’effectuant dans le respect des principes posés par le RGPD et la CNIL (Commission Nationale de l’Informatique et des Libertés).
  • La diffusion sécurisée des résultats aux patients qui peuvent ainsi appliquer immédiatement les mesures de prévention, ainsi qu’aux prescripteurs et la mise à disposition des codes d’activation uniques pour l’application STOP COVID.
  • La mise à disposition de données de qualité, consolidées et pseudonymisées en temps réel à destination de Santé public France, de la direction de la recherche, des études, de l’évaluation et des statistiques (DREES) et de la plateforme Health Data Hub (mise en place par le gouvernement français), à des fins statistiques et de surveillance épidémiologique.

Dans une première étape, les sites publics, principalement des centres hospitaliers universitaires, équipés de système MGI, ont été connectés à la plateforme SI-DEP. Ces automates sont venues soutenir la forte augmentation des capacités de tous les laboratoires équipés pour la réalisation de tests RT-PCR Covid-19.

Dans une deuxième étape, ce sont l’ensemble des laboratoires français, privés comme publics, qui sont venus intégrer la plateforme nationale. Au total il y a à ce jour 374 centres hospitaliers et environ 4 500 laboratoires privés connectés à la plateforme.

« Ce projet a conduit à la mise en place d’un outil de surveillance qui joue un rôle crucial dans la politique de santé publique, dans un contexte de crise sanitaire inédit. Mené de façon exemplaire grâce à l’engagement de tous les collaborateurs de la société MIPS en France, mais aussi en Belgique, il a pu être mis en production dans des délais exceptionnellement serrés et avec succès puisqu’aujourd’hui, quasiment 100 % des laboratoires sont connectés, » explique Thierry Ginod, directeur du service clients, MIPS.

« Dans un temps record, MIPS a réussi à fournir la solution pour des plateformes nationales de test Covid-19,» conclut John Lebon, président directeur général de MIPS. « En France, notre solution CyberLab a été déployée au cœur du projet SI-DEP ; en Belgique, GLIMS et CyberLab sont exploités pour la plateforme nationale de test et, aux Pays-Bas, tous les laboratoires avec GLIMS ont pu être connectés sur la plateforme nationale CoronIT. Nous sommes particulièrement fiers de soutenir les professionnels de santé qui luttent pour conserver cette crise sanitaire sous contrôle. L’expérience acquise dans différents pays a permis à MIPS de soutenir ces trois projets d’envergure nationale, dans des conditions et des délais exceptionnels. »

Read full article